prompt1 : extract information from  breast pathology report. List the histological classification, i.e. type of cancer or DCIS, subtype, description of any necrosis, any mention of tumor infiltrating lymphocytes,  histological grade, nuclear grade,  lymphovascular invasion, calcification, receptor status, IHC and any other ancillary testing results.  List out and expand the main points.
prompt2 : The report is - Subtype Her2, (A) SENTINEL LYMPH NODE #1, LEFT AXILLA, BIOPSY: One lymph node, no tumor present (0/1). Cytokeratin stain shows no evidence of metastatic carcinoma. (B) SENTINEL LYMPH NODE #2, LEFT AXILLA, BIOPSY: One lymph node, no tumor present (0/1). Cytokeratin stain shows no evidence of metastatic carcinoma. (C) SENTINEL LYMPH NODE #3, LEFT AXILLA, BIOPSY: One lymph node, no tumor present (0/1). Cytokeratin stain shows no evidence of metastatic carcinoma. (DJ LEFT BREAST, SEGMENTAL MASTECTOMY: INVASIVE DUCTAL CARCINOMA OF BREAST, MODIFIED BLACK'S NUCLEAR. GRADE 3 (POORLY. DIFFERENTIATED) (SEE COMMENT). INVASIVE CARCINOMA MEASURES 3.0 CM IN GREATEST DIMENSION GROSSLY. No definitive lymphatic/vascular invasion identified. FOCAL INTRADUCTAL CARCINOMA (DCIS), MODIFIED BLACK'S NUCLEAR GRADE. 3 (HIGH GRADE),. SOLID AND CRIBRIFORM TYPES WITH NECROSIS, COMPRISING. APPROXIMATELY 10% OF TUMOR. INVASIVE AND IN SITU CARCINOMA ARE 0.5 CM TO THE CLOSEST ANTERIOR. MARGIN. Remaining surgical margins are widely free of tumor. (E) SENTINEL LYMPH NODE #4, LEFT AXILLA, BIOPSY: Benign fibroadipose tissue, no lymph node or tumor present. Entire report and diagnosis completed by. COMMENT. Immunohistochemical staining is performed on a representative formalin-fixed, paraffin-. embedded section of INVASIVE CARCINOMA, left breast, block D6. MARKER. % POSITIVE. SCORE. Estrogen Receptor. Negative. 0%. N/A. Progesterone Receptor. Negative. 0%. N/A. HER-2/neu. overexpression. Negative. 1+. Due to the above HER-2/neu immunohistochemical staining result, gene copy level (HER-2/neu: CEP17 signal ratio) will be evaluated by FISH and a separate report will be issued. FOOTNOTE. Estrogen receptor was assessed by immunohistochemistry using antibody 6F11 (. Progesterone receptor was assessed by immunohistochemistry using antibody PgR1294(. HER-2/neu was assessed by immunohistochemistry using antibody AB8 1. GROSS DESCRIPTION. (A) SENTINEL LYMPH NODE #1, LEFT AXILLA, IN VIVO 69, EX VIVO 55, BLUE - Two. fragments of tissue including one lymph node measures 2.0 x 1.5 x 0.8 cm. Serially sectioned. Touch preparation performed. SECTION CODE: A1, A2, one lymph node; A3, A4, second fragment of tissue. TP/DX: NO TUMOR PRESENT. (B) SENTINEL LYMPH NODE #2, LEFT AXILLA, BLUE, IN VIVO 21, EX VIVO 39 - A single. lymph node (2.5 x 1.8 x 1.0 cm). Serially sectioned. Touch preparation performed. Entirely submitted. SECTION CODE: B1-B3, one lymph node serially sectioned. TP/DX: NO TUMOR PRESENT. (C) SENTINEL LYMPH NODE #3, LEFT AXILLA, BLUE, IN VIVO 15, EX VIVO 5 - A single. lymph node (1.0 x 0.8 x 0.5 cm). Serially sectioned. Touch preparation performed. SECTION CODE: C, one lymph node serially sectioned. TP/DX: NO TUMOR PRESENT. (D) LEFT BREAST, SEGMENTAL MASTECTOMY, SHORT STITCH SUPERIOR, LONG. STITCH LATERAL - The specimen consists of an oriented segmental mastectomy measuring. 9.0 x 6.0 x 3.5 cm. Serially sectioned to reveal a 3.0 cm mass, which is 0.5 cm to the closest. anterior margin. Remaining surgical margins are widely free of tumor. The specimen is x-rayed,. and a surgical clip is identified within the tumor (slice #4). Suspicious areas are circled by the. radiologist for sampling. INK CODE: Superior - blue, anterior - yellow, inferior - green, medial and lateral - red,. deep black. SECTION CODE: D1, perpendicular sections of medial margin; D2-D5, circled by. radiologist in slice #3 with anterior margin; D6, D7, tumor/clipped area in slice #4 (mirror images);. D8, anterior margin, slice #4; D9, inferior margin, slice #4; D10, deep margin, slice #4; D11,. superior margin, slice #4; D12, D13, remaining tumor area in slice #4; D14-D16, circled by the. radiologist in slice #5; D17, inferior and deep margin, slice #5; D18, remaining tumor area in slice. #5; D19, D20, circled by radiologist in slice #6; D21, D22, circled by radiologist in slice #7; D23,. perpendicular sections of lateral margin. (E) SENTINEL LYMPH NODE #4, BLUE, LEFT AXILLA IN VIVO 20, EX VIVO 20 - An irregular. fragment of fibroadipose tissue (3.0 x 2.0 x 0.6 cm). Serially sectioned and no lymph nodes. grossly identified. The specimen is entirely submitted in E1-E3. CLINICAL HISTORY. Newly diagnosed left breast cancer. SNOMED CODES. T-04050, M-85003, M-85002, T-C4714, M-00110. "Some tests reported here may have been developed and performance characteristics. determined by. These tests have not been. specifically cleared or approved by the U.S. Food and Drug Administration. Released by: Start of ADDENDUM. ADDENDUM. Addendum completed by I. SPECIMEN SOURCE. Left breast. SUMMARY. Tissue section of the invasive carcinoma. D6 was evaluated for HER-2/neu gene. amplification by interphase fluorescence in situ hybridization technique using the PathVysion. HER-2/neu DNA Probe Kit (LSI HER-2/neu. //CEP17. Slide adequacy is satisfactory. Sixty tumor nuclei were counted and showed an average of 1.67. copies of LSI HER-2/neu gene per nucleus and an average of 1.50 copies of CEP17 per nucleus. Negative and positive controls (established by. ) with this batch are. appropriate. Two representative images have been archived. INTERPRETATION. The tumor cells demonstrated no amplification of the HER-2/neu gene copy levels (HER-2/neu: CEP17 signal ratio: 1.11). The following guideline has been established for HER-2/neu testing: Normal HER-2/neu levels: <1.80; Equivocal HER-2/neu levels: 1.80 - 2.20; Amplified HER-2/neu. levels: >2.20. (Ref: Arch Pathol Lab Med. 2007; 131:18-43). NOTES. The LSI HER-2/neu probe is specific for the HER-2/neu gene Locus (17q 11.2-q12) and the CEP. 17 DNA probe is specific for the alpha satellite DNA sequence at the centromeric region of. Chromosome 17 (17 p11.1-q11.2). This test has been cleared and approved for specific uses by the U.S. Food and Drug. Administration. Its system is operating within the performance specifications stated in the product. insert. Released by:

expanded version (tokens=2159) : 
 Histological Classification: 
1. Invasive ductal carcinoma of the breast, modified Black's nuclear grade 3 (poorly differentiated)
2. Focal intraductal carcinoma (DCIS), modified Black's nuclear grade 3 (high grade), solid and cribriform types with necrosis comprising approximately 10% of tumor 
Subtype: HER2
Necrosis: Present in 10% of the tumor
Tumor Infiltrating Lymphocytes: Not mentioned
Histological Grade: Modified Black's nuclear grade 3 (poorly differentiated) for invasive carcinoma and modified Black's nuclear grade 3 (high grade) for DCIS 
Nuclear Grade: Grade 3 (poorly differentiated)
Lymphovascular Invasion: No definitive lymphatic/vascular invasion identified
Calcification: Not mentioned
Receptor Status: 
1. Estrogen receptor- Negative 
2. Progesterone receptor- Negative
3. HER-2/neu - Overexpression Negative (1+) on initial immunohistochemical staining. However, HER-2/neu gene amplification was later ruled out by PathVysion HER-2/neu DNA Probe Kit
Ancillary testing results: Gene copy level (HER-2/neu: CEP17 signal ratio) was evaluated by FISH to rule out HER-2/neu gene amplification. Two representative images were archived and demonstrated no amplification of the HER-2/neu gene

prompt : Please generate a succinct report in 75 words from the above information. Exclude any filler words or sentences. If something is not mentioned or specified, exclude it from the report. Low verbosity.

final output (tokens=2316) : 
 Report:
Left breast pathology: invasive ductal carcinoma and focal intraductal carcinoma (DCIS) with HER2 subtype. No tumor present in sentinel lymph nodes. Necrosis present in approximately 10% of tumor. Modified Black's nuclear grade 3 for both types of carcinoma. Estrogen and progesterone receptors were negative, and HER-2/neu was initially overexpressed (1+), but later ruled out by FISH testing. Gene copy level analysis showed no amplification of the HER-2/neu gene.

